eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
eXoZymes, Inc.NASDAQ: EXOZ
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $74.15K rose 5.2% year over year, ahead of the -179.7% change in trailing-twelve-month depreciation & amortization.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.2% holds above the trailing-twelve-month pace of -179.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (52.91K) USD
- Year-over-year change
- -119.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.91K) | -119.8% |
| FY2024 | 2024-12-31 | 267.38K | +35.8% |
| FY2023 | 2023-12-31 | 196.94K | +33.3% |
| FY2022 | 2022-12-31 | 147.75K | +148.7% |
| FY2021 | 2021-12-31 | 59.41K | — |
Depreciation & Amortization vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -179.7% is the lowest of 7, against a peer median of -76.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| FY2025 | $234K USD | +136.2% | +77.9% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $219.19K USD | -179.7% | — | — |
| LTM Mar 2026 | CA$75.25K CAD | -81.1% | -37.4% | — | |
| LTM Mar 2026 | $48K USD | -98.5% | -55.3% | — | |
| LTM Mar 2026 | $876 USD | -75.7% | -21.0% | — | |
| Peer median (excluding EXOZ) | — | -76.4% | -28.0% | 4.1% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | (52.91K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 198.46K | 216.5K | 281.54K | 1.13M | 1.99M |
| Change in Working Capital | (536.48K) | (190.07K) | 220.31K | (4.02M) | 380.17K |
| Accounts Receivables | (317.07K) | (341.18K) | (72.79K) | 145.04K | 114.72K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (214.43K) | 118.5K | 272.89K | 221.34K | 311.09K |
| Other Working Capital | (4.99K) | 32.61K | 20.21K | (4.38M) | (45.63K) |
| Other Non-Cash Items | (99K) | (35.15K) | 158.73K | (19.4K) | 341.33K |
| Operating Cash Flow | (1.59M) | (1.26M) | (1.18M) | (8.51M) | (6.5M) |
| Capital Expenditures | (422.59K) | (185.98K) | (288.71K) | (396.45K) | (169.92K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 110.33K | 98.77K | (22.46K) | 37.24K | 19.7K |
| Investing Cash Flow | (312.25K) | (87.21K) | (311.17K) | (359.22K) | (150.22K) |
| Debt Repayment | 0 | 0 | 0 | 3.98M | (27.71K) |
| Common Stock Issued | 2.31M | 1.36M | 0 | 14.53M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1M | 11.82K | 0 |
| Financing Cash Flow | 2.31M | 1.36M | 1M | 18.52M | (27.71K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 413.45K | 10.76K | (492.04K) | 9.65M | (6.68M) |
| Free Cash Flow | (2.01M) | (1.44M) | (1.47M) | (8.9M) | (6.67M) |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.